Evaluation of Pfizer Vaccine Efficacy and Effect on Thrombosis in Type-2 Diabetes Mellitus Iraqi Patients

Abstract

Background diabetes mellitus type 2 is associated with the highest risk of SARS-CoV-2 and complications, Vaccination against COVID-19 is highly effective in reducing mortality and morbidity in T2DM objectives The effect of the Pfizer vaccine on humoral immune responses in T2DM was measured by measuring serum Anti-Nucleocapsid SARS-CoV-2-Specific IgG Concentration Antibodies and detecting an effect on D-dimer and platelets after the second dose of the Pfizer vaccine. Methods Venous blood was collected following the second dosage of vaccination, serum Anti-Nucleocapsid SARS-CoV-2-Specific IgG concentration was assayed by ichroma-2 sandwich immunodetection method in which fluorescence and D-dimer measured by HiproBiotechnology (Nephelometry immunoassay). Results the results revealed the efficacy of the Pfizer vaccine in a diabetic is low in comparison to controls while D-dimer is higher in diabetics and lower in controls and platelets are higher in diabetics and lower in controls. Conclusion these results showed lower efficacy of the Pfizer vaccine in diabetics in comparison with control in regard to the studied parameters and the Pfizer vaccine does not effect on thrombosis.